Ovid Therapeutics' OV329 Shows Promising Safety and Efficacy in Phase 1 Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 18 2026
0mins
Should l Buy OVID?
Source: NASDAQ.COM
- Drug Development Progress: Ovid Therapeutics defines OV329 as a 'next-generation GABA-AT inhibitor' aimed at treating rare and treatment-resistant epilepsy and seizures, with management asserting it is more potent and safer than the first-generation drug Vigabatrin, showcasing the company's innovative potential in neurology.
- Promising Safety Data: The latest Phase 1 trial of OV329 at a 7 mg dose reported 'no treatment-related adverse events,' and ophthalmic assessments showed no evidence of ocular or retinal changes associated with OV329, establishing a solid foundation for further development.
- Funding for R&D: Ovid announced a $60 million private placement to support OV329's development in additional indications, including tuberous sclerosis complex seizures and infantile spasms, demonstrating the company's strong commitment to advancing its drug pipeline.
- Positive Stock Reaction: Ovid Therapeutics' stock rose over 18% today, reflecting market optimism regarding OV329 and indicating investor confidence in the company's potential impact on epilepsy treatment in the future.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OVID?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OVID
Wall Street analysts forecast OVID stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.300
Low
2.00
Averages
4.17
High
7.00
Current: 2.300
Low
2.00
Averages
4.17
High
7.00
About OVID
Ovid Therapeutics Inc. is a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need. It is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. It develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. It also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ovid Therapeutics Stock Surges 18% on Positive OV329 Data
- Stock Surge: Ovid Therapeutics' stock rose over 18% as of midnight today, reflecting strong market confidence in the company's future prospects following positive news regarding its drug candidate OV329.
- Drug Development Progress: OV329, a next-generation GABA-AT inhibitor aimed at treating rare and treatment-resistant epilepsy, is believed by management to be more potent than the first-generation drug Vigabatrin, with a better safety and tolerability profile, potentially improving patient quality of life significantly.
- Clinical Trial Results: The latest Phase 1 trial results showed no treatment-related adverse events in the 7 mg cohort, and ophthalmic assessments revealed no evidence of ocular or retinal changes associated with OV329, indicating promising safety data.
- Funding Plan: The company announced a $60 million private placement intended to support the development of OV329 for other indications, including tuberous sclerosis complex seizures and infantile spasms, as well as a Phase 2 trial for focal onset seizures in drug-resistant patients, providing crucial funding for future growth.
See More
Ovid Therapeutics' OV329 Shows Promising Safety and Efficacy in Phase 1 Study
- Drug Development Progress: Ovid Therapeutics defines OV329 as a 'next-generation GABA-AT inhibitor' aimed at treating rare and treatment-resistant epilepsy and seizures, with management asserting it is more potent and safer than the first-generation drug Vigabatrin, showcasing the company's innovative potential in neurology.
- Promising Safety Data: The latest Phase 1 trial of OV329 at a 7 mg dose reported 'no treatment-related adverse events,' and ophthalmic assessments showed no evidence of ocular or retinal changes associated with OV329, establishing a solid foundation for further development.
- Funding for R&D: Ovid announced a $60 million private placement to support OV329's development in additional indications, including tuberous sclerosis complex seizures and infantile spasms, demonstrating the company's strong commitment to advancing its drug pipeline.
- Positive Stock Reaction: Ovid Therapeutics' stock rose over 18% today, reflecting market optimism regarding OV329 and indicating investor confidence in the company's potential impact on epilepsy treatment in the future.
See More
Coherent Corp. Shares Rise 6% Ahead of OFC 2026 Showcase
- Stock Performance: Coherent Corp.'s shares are climbing approximately 6% in Wednesday morning trading, currently priced at $260.86, reflecting a 6.10% increase from the opening price of $251.94, indicating strong market optimism about its future performance.
- Trading Volatility: The stock has reached a high of $265.80 during today's session, with a yearly trading range of $45.58 to $300.20, showcasing investor confidence in the company's innovative capabilities.
- Technology Showcase: The company will highlight the breadth and scalability of its Indium Phosphide (InP) innovations at OFC 2026, covering high-power lasers, advanced modulators, photodiodes, and integrated subsystems, underscoring its technological leadership in AI-driven networks.
- Strategic Commitment: By expanding its InP platform, Coherent Corp. demonstrates its commitment to delivering the performance, scalability, and manufacturing depth required to meet the growing demands of AI networks, thereby enhancing its competitive position in the market.
See More
Health Care Stocks Decline in Premarket Trading
- Market Trend: Health care stocks are generally declining in premarket trading on Wednesday, reflecting a cautious investor sentiment likely influenced by overall market emotions and economic data.
- Sector Impact: The drop in the Health Care Select Sector Index may affect the stock performance of related companies, especially amid unclear future earnings expectations from investors.
- Investor Reaction: As market volatility increases, investors may reassess the investment value of health care stocks, leading to capital outflows that further exacerbate downward pressure on stock prices.
- Economic Context: Given the heightened economic uncertainty, the performance of the health care sector may be more significantly impacted, prompting investors to closely monitor relevant policies and market dynamics.
See More
Ovid Therapeutics Shares Surge 26% on Positive Clinical Data and Financing
- Clinical Data Release: Ovid Therapeutics unveiled clinical data for its next-generation GABA-aminotransferase inhibitor OV329, demonstrating favorable safety and tolerability at a 7 mg dose, indicating its potential as a best-in-class therapy for drug-resistant epilepsy.
- Program Expansion Plans: The company plans to initiate a Phase 2 randomized controlled trial of OV329 in Q2 2026 to evaluate two dose levels for treatment-resistant focal onset seizures, further advancing its neurology pipeline.
- Financing Support: Ovid secured $60 million in PIPE financing led by Point72, which will fund new indications for OV329 and OV4071, with the deal expected to close on March 19, 2026, enhancing the company's financial position for pipeline development.
- Improved Financial Performance: Ovid reported a net income of $9.7 million in Q4 2025, translating to $0.06 per share, a significant turnaround from a net loss of $9.3 million in 2024, reflecting strengthened financial health and growth potential.
See More
Ovid Therapeutics Shares Surge Over 40% on Positive OV329 Drug Results
- Drug Safety Breakthrough: Ovid Therapeutics reported that its OV329 drug demonstrated favorable safety and tolerability at a 7 mg dose, with no treatment-related adverse events, thereby supporting its potential as a best-in-category drug and significantly enhancing the company's competitive position in the epilepsy treatment market.
- Clinical Trial Expansion: The company plans to initiate an open-label photoparoxysmal response study to evaluate the anti-seizure effects of OV329 while advancing a Phase 2 randomized, placebo-controlled trial expected to assess two dose levels and determine seizure reduction efficacy in patients with treatment-resistant focal onset seizures, further validating the drug's clinical application potential.
- Funding to Support R&D: Ovid announced a private investment in public equity financing expected to yield $60 million in gross proceeds, led by Point72 with participation from existing investors, with funds earmarked for expanding OV329's development and supporting general R&D, thereby strengthening the company's financial foundation.
- Financial Performance Improvement: Ovid reported a net income of $9.7 million for Q4, compared to a net loss of $9.3 million for the same period in 2024, indicating significant financial improvement and boosting market confidence in its future growth prospects.
See More
Ovid Therapeutics Stock Surges 18% on Positive OV329 Data
- Stock Surge: Ovid Therapeutics' stock rose over 18% as of midnight today, reflecting strong market confidence in the company's future prospects following positive news regarding its drug candidate OV329.
- Drug Development Progress: OV329, a next-generation GABA-AT inhibitor aimed at treating rare and treatment-resistant epilepsy, is believed by management to be more potent than the first-generation drug Vigabatrin, with a better safety and tolerability profile, potentially improving patient quality of life significantly.
- Clinical Trial Results: The latest Phase 1 trial results showed no treatment-related adverse events in the 7 mg cohort, and ophthalmic assessments revealed no evidence of ocular or retinal changes associated with OV329, indicating promising safety data.
- Funding Plan: The company announced a $60 million private placement intended to support the development of OV329 for other indications, including tuberous sclerosis complex seizures and infantile spasms, as well as a Phase 2 trial for focal onset seizures in drug-resistant patients, providing crucial funding for future growth.
See More
Ovid Therapeutics' OV329 Shows Promising Safety and Efficacy in Phase 1 Study
- Drug Development Progress: Ovid Therapeutics defines OV329 as a 'next-generation GABA-AT inhibitor' aimed at treating rare and treatment-resistant epilepsy and seizures, with management asserting it is more potent and safer than the first-generation drug Vigabatrin, showcasing the company's innovative potential in neurology.
- Promising Safety Data: The latest Phase 1 trial of OV329 at a 7 mg dose reported 'no treatment-related adverse events,' and ophthalmic assessments showed no evidence of ocular or retinal changes associated with OV329, establishing a solid foundation for further development.
- Funding for R&D: Ovid announced a $60 million private placement to support OV329's development in additional indications, including tuberous sclerosis complex seizures and infantile spasms, demonstrating the company's strong commitment to advancing its drug pipeline.
- Positive Stock Reaction: Ovid Therapeutics' stock rose over 18% today, reflecting market optimism regarding OV329 and indicating investor confidence in the company's potential impact on epilepsy treatment in the future.
See More
Coherent Corp. Shares Rise 6% Ahead of OFC 2026 Showcase
- Stock Performance: Coherent Corp.'s shares are climbing approximately 6% in Wednesday morning trading, currently priced at $260.86, reflecting a 6.10% increase from the opening price of $251.94, indicating strong market optimism about its future performance.
- Trading Volatility: The stock has reached a high of $265.80 during today's session, with a yearly trading range of $45.58 to $300.20, showcasing investor confidence in the company's innovative capabilities.
- Technology Showcase: The company will highlight the breadth and scalability of its Indium Phosphide (InP) innovations at OFC 2026, covering high-power lasers, advanced modulators, photodiodes, and integrated subsystems, underscoring its technological leadership in AI-driven networks.
- Strategic Commitment: By expanding its InP platform, Coherent Corp. demonstrates its commitment to delivering the performance, scalability, and manufacturing depth required to meet the growing demands of AI networks, thereby enhancing its competitive position in the market.
See More
Health Care Stocks Decline in Premarket Trading
- Market Trend: Health care stocks are generally declining in premarket trading on Wednesday, reflecting a cautious investor sentiment likely influenced by overall market emotions and economic data.
- Sector Impact: The drop in the Health Care Select Sector Index may affect the stock performance of related companies, especially amid unclear future earnings expectations from investors.
- Investor Reaction: As market volatility increases, investors may reassess the investment value of health care stocks, leading to capital outflows that further exacerbate downward pressure on stock prices.
- Economic Context: Given the heightened economic uncertainty, the performance of the health care sector may be more significantly impacted, prompting investors to closely monitor relevant policies and market dynamics.
See More
Ovid Therapeutics Shares Surge 26% on Positive Clinical Data and Financing
- Clinical Data Release: Ovid Therapeutics unveiled clinical data for its next-generation GABA-aminotransferase inhibitor OV329, demonstrating favorable safety and tolerability at a 7 mg dose, indicating its potential as a best-in-class therapy for drug-resistant epilepsy.
- Program Expansion Plans: The company plans to initiate a Phase 2 randomized controlled trial of OV329 in Q2 2026 to evaluate two dose levels for treatment-resistant focal onset seizures, further advancing its neurology pipeline.
- Financing Support: Ovid secured $60 million in PIPE financing led by Point72, which will fund new indications for OV329 and OV4071, with the deal expected to close on March 19, 2026, enhancing the company's financial position for pipeline development.
- Improved Financial Performance: Ovid reported a net income of $9.7 million in Q4 2025, translating to $0.06 per share, a significant turnaround from a net loss of $9.3 million in 2024, reflecting strengthened financial health and growth potential.
See More
Ovid Therapeutics Shares Surge Over 40% on Positive OV329 Drug Results
- Drug Safety Breakthrough: Ovid Therapeutics reported that its OV329 drug demonstrated favorable safety and tolerability at a 7 mg dose, with no treatment-related adverse events, thereby supporting its potential as a best-in-category drug and significantly enhancing the company's competitive position in the epilepsy treatment market.
- Clinical Trial Expansion: The company plans to initiate an open-label photoparoxysmal response study to evaluate the anti-seizure effects of OV329 while advancing a Phase 2 randomized, placebo-controlled trial expected to assess two dose levels and determine seizure reduction efficacy in patients with treatment-resistant focal onset seizures, further validating the drug's clinical application potential.
- Funding to Support R&D: Ovid announced a private investment in public equity financing expected to yield $60 million in gross proceeds, led by Point72 with participation from existing investors, with funds earmarked for expanding OV329's development and supporting general R&D, thereby strengthening the company's financial foundation.
- Financial Performance Improvement: Ovid reported a net income of $9.7 million for Q4, compared to a net loss of $9.3 million for the same period in 2024, indicating significant financial improvement and boosting market confidence in its future growth prospects.
See More
